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Genome-Wide Association Analysis Reveals Genetic
Heterogeneity of Sj€ogren’s Syndrome According to Ancestry
Kimberly E. Taylor,1 Quenna Wong,2 David M. Levine,2 Caitlin McHugh,2 Cathy Laurie,2
Kimberly Doheny,3 Mi Y. Lam,1 Alan N. Baer,3 Stephen Challacombe,4 Hector Lanfranchi,5
Morten Schiødt,6 M. Srinivasan,7 Hisanori Umehara,8 Frederick B. Vivino,9
Yan Zhao,10 Stephen C. Shiboski,1 Troy E. Daniels,1 John S. Greenspan,1
Caroline H. Shiboski,1 and Lindsey A. Criswell1
Objective. The Sj€ogren’s International Collabora-
tive Clinical Alliance (SICCA) is an international data
registry and biorepository derived from amultisite observa-
tional study of participants in whom genotyping was per-
formed on theOmni2.5Mplatform and who had undergone
deep phenotyping using common protocol-directed meth-
ods. The aim of this study was to examine the genetic etiol-
ogy of Sj€ogren’s syndrome (SS) across ancestry and disease
subsets.
Methods. We performed genome-wide association
study analyses using SICCA subjects and external controls
obtained from dbGaP data sets, one using all participants
(1,405 cases, 1,622 SICCA controls, and 3,125 external con-
trols), one using European participants (585, 966, and 580,
respectively), and one using Asian participants (460, 224,
and 901, respectively) with ancestry adjustments via princi-
pal components analyses. We also investigated whether
subphenotype distributions differ by ethnicity, and whether
this contributes to the heterogeneity of genetic associations.
Results. We observed significant associations in
established regions of the major histocompatibility com-
plex (MHC), IRF5, and STAT4 (P5 3 3 10242, P5 3 3
10214, and P5 9 3 10210, respectively), and several novel
suggestive regions (those with 2 or more associations at
P< 1 3 1025). Two regions have been previously impli-
cated in autoimmune disease: KLRG1 (P5 6 3 1027
[Asian cluster]) and SH2D2A (P5 2 3 1026 [all partici-
pants]). We observed striking differences between the asso-
ciations in Europeans and Asians, with high heterogeneity
especially in the MHC; representative single-nucleotide
polymorphisms from established and suggestive regions
had highly significant differences in the allele frequencies
in the study populations. We showed that SSA/SSB autoan-
tibody production and the labial salivary gland focus score
criteria were associated with the first worldwide principal
component, indicative of higher non-European ancestry
(P5 4 3 10215 and P5 4 3 1025, respectively), but that
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subphenotype differences did not explain most of the
ancestry differences in genetic associations.
Conclusion. Genetic associations with SS differ
markedly according to ancestry; however, this is not
explained by differences in subphenotypes.
Sj€ogren’s syndrome (SS) is a systemic autoim-
mune disease affecting primarily the lacrimal and sali-
vary glands and occurs in ;0.5–1% of the population
(1). Patients typically present with dry eyes and/or dry
mouth, but confirmation of the diagnosis using Ameri-
can College of Rheumatology (ACR) classification crite-
ria requires a positive result for any 2 of the 3 following
tests: presence of SS autoantibodies (primarily SSA and
SSB), presence of focal lymphocytic sialadenitis in labial
salivary gland (LSG) biopsy, and degree of eye damage
due to keratoconjunctivitis sicca (KCS) (2).
While there have been relatively few family studies in
SS compared to the number of family studies in other auto-
immune diseases, there is an increased prevalence of autoim-
mune diseases in families with SS (3), and the sibling risk
ratio in a Taiwanese population was recently estimated to be
19% (4). Genetic variants in multiple HLA class II genes in
the major histocompatibility complex (MHC) region 6p21.3
have been well established as SS risk factors (5). More
recently, a genome-wide association study (GWAS) of SS in
subjects of European descent (6) established associations of
SS with gene regions IRF5–TNP03, STAT4, IL12A,
FAM167A–BLK, DDX6–CXCR5, and TNIP1. In addition, a
GWAS of SS in Han Chinese participants identified GTF2I
as a susceptibility locus in that population (7).
The Sj€ogren’s International Collaborative Clinical
Alliance (SICCA) is an international data registry and
biorepository derived from amultisite observational study for
which participants were enrolled between 2004 and 2012
from the University of Buenos Aires, Argentina; Peking
Union Medical College, Beijing, China; Rigshopitalet,
Copenhagen, Denmark; Kanazawa Medical University,
Ishikawa, Japan; King’s College, London, UK; University of
California, San Francisco (UCSF), California; Aravind
Eye Hospital, Madurai, India; Johns Hopkins University
(JHU), Baltimore,Maryland; andUniversity of Pennsylvania,
Philadelphia, Pennsylvania. In addition to whole-genome
genotyping, SICCA participants underwent extensive
phenotyping using common comprehensive protocol-
directed methods for collection of data and specimens across
all sites (2,8). More information about the SICCA registry is
available online at http://sicca-online.ucsf.edu. SICCA col-
laborators in addition to those who are authors are listed in
AppendixA.
Although the small set of genes described above
have been identified as contributing to SS susceptibility,
relatively little is known compared with what is known
about other autoimmune diseases, particularly how suscep-
tibility and severity are affected by ancestry and how sub-
phenotypes may be influenced by different genes and/or
ethnicity. For example, in systemic lupus erythematosus
(SLE), Northern Europeans have less severe disease
including lower susceptibility for nephritis (9,10), and
double-stranded DNA (dsDNA)–negative SLE has a
genetic profile different from that of dsDNA-positive SLE
(11). One population-based study of SS in a multiethnic
cohort in the greater Paris area showed that non-
European participants had a higher prevalence of SS, were
younger, and were more likely to have SS autoantibodies
and polyclonal hypergammaglobulinemia compared with
non-European participants (12).
The SICCA registry offers a unique opportunity to
expand our knowledge of the genetic etiology of SS in 2
principal ways: 1) it is the first international SS cohort
including participants of non-European ancestry and par-
ticipants of European ancestry genotyped together on a
whole-genome platform, and 2) extensive phenotyping
using consistent methods across all sites allows these
genetic data to be analyzed in conjunction with clinical
data on disease manifestations, enabling the combined
effects of genetics, ancestry, and subphenotypes to be
jointly examined.
PATIENTS AND METHODS
Study population and clinical data. SICCA. All SS
patients are SICCA participants who fulfilled the ACR classifica-
tion criteria for primary SS (2). This collection is described in
detail in refs. 2 and 8. All research was approved by an institu-
tional review board or appropriate ethics committee at each
SICCA site. Table 1 shows the distribution of these participants
according to self-reported ethnicity.
Evaluation of the classification criteria relies on the fol-
lowing measures from clinical data that we use in our analysis: 1)
presence of SSA/Ro or SSB/La autoantibodies; 2) a focus score
of .1, measuring the degree of focal sialadenitis in LSG biopsy
specimens (13); and 3) an ocular staining score (OSS) of $3,
measuring the degree of damage due to KCS (14). Fulfillment of
2 of the 3 criteria items described above is sufficient for classifica-
tion as SS according to the ACR. SICCA participants who were
unambiguously negative for SS (i.e., at least 2 of 3 criteria were
known to be negative) were also included in the control group,
along with healthy external (out-of-study) controls (see below).
External controls. Out-of-study controls were obtained
from 3 dbGaP data sets: Age-Related Eye Disease Study
(AREDS; phs000001.v3.p1) Genetic Variation of Refractive
Error Substudy (phs000429.v1.p1), Collaborative Study of Nico-
tine Dependence (COGEND; phs000404.v1.p1), and IgA
Nephropathy GWAS (IGANGWAS; phs000431.v2.p1). Table 1
shows the distribution of these participants according to self-
reported ethnicity (see also SupplementaryMethods, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40040/abstract). Specimens obtained from
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AREDS and COGEND participants were typed on the Illumina
HumanOmni2.5M-4v1 platform, and IGANGWAS participants
were typed on the IlluminaHuman610-Quad v1 platform.
Genotyping and quality assurance. DNA specimens
obtained from SICCA participants were genotyped in 2 phases on
the Illumina HumanOmni2.5-4v1 or Illumina HumanOmni2.5M-
8v1-1 array (2.5 million single-nucleotide polymorphisms [SNPs]
genome-wide) at the Center for Inherited Disease Research.
Quality control and merging of genotypes from the 2 phases were
performed at the University of Washington Genetics Coordinat-
ing Center, as previously described (15). SNPs were removed if
they were monomorphic or positional duplicates; had a missing
call rate of $2%; had 2 or more discordant calls in 170 SICCA
duplicates; had 1 or more discordant calls in 38 cross-phase
SICCA duplicates; had 5 or more Mendelian errors in 76 SICCA
and HapMap trios; had a Hardy-Weinberg equilibrium test P
value of ,1024 in participants with self-identified European
ancestry; or contained large chromosomal anomalies such as
regions of aneuploidy. After quality control was performed (post–
quality control), 1,444,884 SNPs were analyzed; these SICCA
genotype data are available through dbGaP (accession no.
phs000672.v1.p1). For this analysis, SNPs with a minor allele fre-
quency (MAF) of,2%were removed.
Samples with unresolved identity issues (unexpected
duplicates or genotypes inconsistent with expected family structure)
or no case report form were removed. All remaining samples had
call rates of$98%. For this analysis, familymembers were removed
by selecting a maximum set of unrelated (through third-degree rela-
tionships via identical by descent analysis) participants. The num-
bers of post–quality control samples are shown in Table 1.
All external control data sets were filtered to have $2%
MAFs and $98% genotyping of SNPs and individuals. Additional
cross-study quality control performance is described in Supplemen-
tary Methods (available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.40040/abstract). Over-
lap in post–quality control SNPs between the 1,444,884 SNPs from
the Omni2.5M chip and the 483,279 SNPs from the Illumina 610K
chip resulted in 302,689 SNPs for analyses in the Asian cluster,
which included IGANGWAS controls; this is hereinafter referred
to as the 300K overlap SNP set.
Statistical analysis. Ancestry. Principal components
analysis (PCA) using EigenStrat (16) was used for ancestry
estimation (see Supplementary Methods, available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.40040/abstract). Three PCAs were performed: an
intercontinental PCA of all participants (see Supplementary Fig-
ure 1, available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40040/abstract), yielding
PC1 (principal component 1), PC2, and so on; an intracontinental
PCA of a European-only cluster (Supplementary Figure 2), yield-
ing EPC1 (European PC1), EPC2, and so on; and an
intracontinental PCA of an Asian-only cluster (Supplementary
Figure 3), yielding APC1 (Asian PC1), APC2, and so on. The
Asian cluster was also split into Chinese and Japanese clusters
(APC1.0, APC1,0) for some analyses.
Based on the leveling of the scree plots, we used EPC1 to
adjust for ancestry within the European cluster, and we used
APC1 andAPC2 to adjust for ancestry within the Asian cluster. In
the intercontinental PCA, the top 4 PCs were sufficient to cluster
major populations: PC1 differentiated European versus Asian;
similarly, PC2 differentiated African ancestry, PC3 differentiated
American Indian ancestry, and PC4 differentiated Indian ances-
try. PCs 5–9 were each highly correlated with one of the top 3
European or top 2 Asian PCs (see Supplementary Methods,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40040/abstract); therefore,
we adjusted for 9 PCs in our all-subjects regressions to account for
both intercontinental substructure and the intracontinental sub-
structure of these population groups.
GWAS. Due to the multiethnic and multiplatform
nature of our study, we performed multiple phases of analysis
using logistic regression for each SNP as a predictor of case–
control status: 1) analysis of all SICCA participants and external
controls (AREDS and COGEND) genotyped on the Omni2.5M
platform (1,444,854 SNPs), adjusting for 9 PCs, sex, and smoking
status (see Supplementary Methods, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40040/abstract); 2) analysis of only the European cluster,
adjusting for the top intra-European PC (EPC1), sex, and
smoking status (see Supplementary Methods); 3) meta-analysis of
the 2 Asian clusters, including Chinese external controls
(IGANGWAS) typed on the Illumina 610 Quad, for SNPs in the
300K overlap set. Analysis of the China and Japan subgroups
were performed via logistic regression, adjusting for the top 2
Table 1. Numbers of participants according to data source and self-reported ethnicity*
Registry European African Asian
Hispanic/Native
American
Mixed/other/
unspecified
SICCA
All† 1,840 83 913 358 161
Participants with SS 669 51 570 164 59
Participants without SS 1,109 31 306 191 101
AREDS 1,659 0 0 0 0
COGEND 910 464 0 46 47
IGANGWAS 0 0 897 0 0
HapMap 18 11 8 16 0
* SICCA5 Sj€ogren’s International Collaborative Clinical Alliance; SS5 Sj€ogren’s syndrome; AREDS5Age-
Related Eye Disease Study; COGEND5Collaborative Study of Nicotine Dependence; IGANGWAS5 IgA
Nephropathy genome-wide association study (GWAS).
† Includes participants with an ambiguous SS classification due to missing data and participants with second-
ary SS not included in the GWAS.
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Figure 1. Manhattan plots of the results of the genome-wide association studies (GWAS) with logistic regression in patients with Sj€ogren’s syn-
drome. A, Global GWAS (1,405 cases, 1,622 Sj€ogren’s International Collaborative Clinical Alliance [SICCA] controls, and 3,125 external con-
trols) using 1,444,854 single-nucleotide polymorphisms (SNPs), with adjustment for 9 intercontinental principal components (PCs) and smoking
(l5 1.02). B, European subgroup GWAS (585 cases, 966 SICCA controls, and 580 external controls) using the same set of SNPs described in A,
with adjustment for 1 intra-European PC and smoking (l5 1.002). C, Meta-analysis of the Chinese (l5 1.03) and Japanese (l5 1.03) subgroups
of the Asian GWAS (460 cases, 224 SICCA controls, and 901 external controls) using 302,688 SNPs, with adjustment for 2 intra-Asian PCs.
Insets, Q–Q plots. MHC5major histocompatibility complex; Chr.5 chromosome.
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intra-Asian PCs (APC1 and APC2) and sex. The number of
subjects included in each analysis is described in Figure 1 and Sup-
plementary Table 1 (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40040/
abstract).
Regulatory evidence for sites of interest was collected from
RegulomeDB (17) andANNOVAR (18) data; evidence for associ-
ation with related phenotypes was collected from National Center
for Biotechnology Information Phenotype–Genotype Integrator
(http://www.ncbi.nlm.nih.gov/gap/phegeni). For follow-up in the
KLRG1 region, we imputed genotypes for all European and Asian
participants up to the 1000 Genomes reference panel starting from
the 300Koverlap SNP set, using IMPUTE2 software (19).
SNP selection for downstream analyses. We undertook
several analyses in order to determine whether or not the appar-
ent differences between Asian and European associations were
true heterogeneity of association or were attributable to other
factors such as differences in allele frequency between popula-
tions or disease heterogeneity between population groups and/or
sites. For these analyses and for multivariate modeling, we chose
representative SNPs from our case–control analyses: one SNP
per region with at least 2 associations that were suggestive (P 3
1025) or stronger in any of our 3 GWAS (all participants, Euro-
pean cluster, and Asian cluster). We also selected representative
SNPs from the top hits in published European (6) and Asian (7)
GWAS. SNPs with the strongest association from the 300K over-
lap set were selected to allow comparisons and multivariate
modeling with our full Asian control data; in some cases, a proxy
SNP was chosen. A total of 24 SNPs were selected (see Supple-
mentary Methods and Supplementary Table 2, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40040/abstract).
Heterogeneity. We quantified heterogeneity between the
European and Asian GWAS using Q and I2 statistics from meta-
analysis of the 2 studies, using Plink. For theMHC region, we also
imputed HLA alleles using SNP2HLA (20) and the HapMap
CEU (Utah residents with ancestry from northern and western
Europe) reference panel for the Europeans and a Pan-Asian
Table 2. Top SNPs in regions having 2 or more suggestive or stronger associations in the case–control analyses*
GWAS Chr. (kbp) Gene region SNP OR 95% CI P
All subjects 1 (156,774) PRCC/SH2D2A rs16837677 1.54 1.29–1.84 2 3 1026
All subjects 1 (156,774) PRCC/SH2D2A rs16837672 1.53 1.28–1.83 2 3 1026
All subjects 2 (191,944) STAT4 rs11889341 1.40 1.26–1.56 9 3 10210
European 2 (191,965) STAT4 rs7574865 1.51 1.31–1.75 2 3 1028
All subjects 2 (191,965) STAT4 rs7574865 1.35 1.21–1.50 5 3 1028
Europeans 2 (191,969) STAT4 rs8179673 1.48 1.28–1.71 8 3 1028
European 3 (14,715) GRIP2/CCDC174 rs79407237 0.61 0.49–0.75 5 3 1026
European 3 (14,682) GRIP2/CCDC174 rs17318848 0.63 0.51–0.77 9 3 1026
European 5 (76,591) PDE8B rs181851 0.67 0.56–0.79 3 3 1026
European 5 (76,600) PDE8B rs11949070 0.67 0.57–0.80 5 3 1026
All subjects 5 (76,620) PDE8B rs10474500 0.75 0.66–0.85 8 3 1026
All subjects 5 (76,553) PDE8B rs10464287 1.53 1.27–1.84 9 3 1026
All subjects 6 (32,591) MHC (HLA–DRB1, HLA–DQA1) rs9271573 2.02 1.82–2.23 3 3 10242
All subjects 6 (32,623) MHC (HLA–DQA1, HLA–DQB1) rs3021302 2.24 1.97–2.54 2 3 10235
European 6 (32,591) MHC (HLA–DRB1/HLA2DQA1) rs9271573 2.29 2.01–2.62 3 3 10234
European 6 (32,679) MHC (HLA–DQB1/HLA–DQA2) rs9275572 2.28 1.99–2.61 7 3 10233
Asian 6 (33,056) MHC (HLA–DPB1) rs9277554 1.65 1.37–2.00 3 3 1027
Asian 6 (33,053) MHC (HLA–DPB1) rs9277464 1.65 1.37–1.99 3 3 1027
All subjects 7 (128,580) IRF5/TNP03 rs3823536 1.49 1.34–1.65 3 3 10214
All subjects 7 (128,716) IRF5/TNP03 rs59110799 1.72 1.49–1.99 3 3 10213
European 7 (128,580) IRF5/TNP03 rs3823536 1.54 1.36–1.76 7 3 10211
European 7 (128,581) IRF5/TNP03 rs3807306 1.50 1.32–1.71 6 3 10210
All subjects 7 (103,405) RELN rs7341475 1.39 1.23–1.57 3 3 1027
All subjects 7 (103,404) RELN rs73180120 1.36 1.20–1.54 1 3 1026
European 7 (103,405) RELN rs7341475 1.43 1.22–1.68 9 3 1026
European 9 (138,947) NACC2 rs4842091 1.39 1.21–1.61 5 3 1026
European 9 (138,948) NACC2 rs11103291 1.39 1.21–1.61 5 3 1026
Asian 12 (9,163) KLRG1/M6PR rs1805673 0.62 0.51–0.74 6 3 1027
Asian 12 (9,154) KLRG1/M6PR rs11048434 0.63 0.53–0.75 6 3 1027
All subjects 13 (47,951) HTR2A/LINC00562 rs7999279 1.42 1.23–1.63 1 3 1026
European 13 (47,951) HTR2A/LINC00562 rs7999279 1.52 1.27–1.81 3 3 1026
European 13 (82,162) LOC105370283-PTMAP5 rs17074492 1.53 1.31–1.79 6 3 1028
European 13 (82,177) LOC105370283-PTMAP5 rs67218188 1.49 1.28–1.74 5 3 1027
All subjects 13 (82,162) LOC105370283-PTMAP5 rs17074492 1.37 1.20–1.56 2 3 1026
All subjects 14 (46,407) MIS18BP1/LINC00871 rs1957173 0.61 0.50–0.74 7 3 1027
All subjects 14 (46,375) MIS18BP1/LINC00871 rs17116722 0.60 0.49–0.74 1 3 1026
All subjects 16 (69,704) NFAT5 rs7192380 1.28 1.16–1.42 2 3 1026
All subjects 16 (69,633) NFAT5 kgp11747098 1.26 1.14–1.40 7 3 1026
European 16 (13,002) SHISA9 rs9938751 0.59 0.48–0.73 1 3 1026
European 16 (12,988) SHISA9 rs8046800 0.61 0.50–0.76 5 3 1026
* Up to 2 single-nucleotide polymorphisms (SNPs) are included for each genome-wide association study (GWAS)/
gene. Chr.5 chromosome; OR5 odds ratio; 95% CI5 95% confidence interval.
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reference panel (described in ref. 21) for the Asians. Associations
with HLA allele doses in each population group were analyzed in
Plink, and the results were meta-analyzed to assess heterogeneity.
In order to investigate or exclude heterogeneity of disease sub-
types, we repeated some analyses using only cases meeting all 3 of
the classification criteria.
RESULTS
Global GWAS. Our global GWAS (Figure 1A) of
the approximately 1.4 million post–quality control SNPs
showed genome-wide significant peaks in established SS
regions, namely the MHC, STAT4, and IRF5. We also
observed several suggestive association peaks, as shown in
Figure 1A and Table 2, with the most significant being in
RELN (odds ratio [OR] 1.4, P5 33 1027) on 7q22.1, and
on 14q21.2 betweenMIS18BP1 and LINC00871 (OR 0.61,
P5 7 3 1027). A suggestive region on 1q23.1 (OR 1.5,
P5 2 3 1026) included SH2D2A, which has been shown
to be associated with other autoimmune disorders. Our
top SNPs in SH2D2A were located in peaks of DNase I
hypersensitivity sites for numerous cell types, and this
region has been shown via ChIP-Seq to bind to protein
CCAAT/enhancer binding protein b (CEBPB), a known
regulator of immune and inflammatory response genes.
Additional suggestive regions were in PDE8B (OR 0.75,
P5 8 3 1026) on 5q13.3 and NFAT5 (OR 1.28, P5 2 3
1026) on 16q22.1.
European versus Asian GWAS. We performed
subpopulation GWAS in our 2 largest ethnic groups. The
European subgroup was analyzed using the same set of 1.4
million SNPs as described above; the Asian group was ana-
lyzed using the 300K set of SNPs overlapping with the
Asian external controls that were added to increase power
for this analysis. Figures 1B and C show Manhattan plots
for the European and Asian GWAS, respectively, and
details of the top SNPs are shown in Table 2. Two aspects
are striking. First, the MHC region, while being the most
significant region in the Asian participants, had a much
weaker effect than that in the Europeans (in Europeans,
peak OR 2.29, 95% confidence interval [95% CI] 2.01–
2.62, P5 3 3 10234; in Asians, peak OR 1.65, 95% CI
1.37–2.00, P5 3 3 1027). Second, the KLRG1 region (for
the top SNP, OR 0.62, P5 6 3 1027) had the next stron-
gest associations in Asians but did not appear to be associ-
ated in Europeans. KLRG1 has been shown to be
associated with SLE (22). Top SNPs in this region show
strong evidence of immune regulation; ChIP-Seq analysis
has shown that they bind to multiple proteins including
NF-kB subunit 1 in B lymphocytes and are within DNase I
hypersensitivity sites of B lymphocytes, Th1 cells, and
Th17 cells.
The European GWAS also showed multiple sug-
gestive association peaks (Figure 1B and Table 2); the
strongest association (OR 1.5, P5 6 3 1028) was in
LOC105370283, a noncoding RNA, on 13q31.1 and near
pseudogene PTMAP5. Other suggestive gene regions were
CCDC174 (OR 0.61, P5 5 3 1026) on 3p25.1, NACC2
(OR 1.39, P5 5 3 1026) on 9q34.3, and SHISA9/
CKAMP44 (OR 0.59, P5 13 1026) on 16p13.12.
MHC region. Figures 2A and B showMHC region
associations in the Asian and European clusters, respec-
tively. In order to determine whether the observed differ-
ences were attributable to power differences, we randomly
selected a subset of the European cases and controls, with
sample sizes equal to those in the Asian analysis (460 cases
and 1,125 controls) and repeated the analysis. Figure 2C
shows the results of that analysis, which continued to dem-
onstrate striking differences in significance and the location
of peaks that are not explained by sample size differences.
The top SNPs in Europeans were rs9271573 (P5 3 3
10234) and rs9275572 (P5 7 3 10233), which flank HLA–
DQA1 and HLA–DQB1, as shown in Figure 2B. The top
SNP in a secondary peak, rs6937545 (P5 6 3 10230), is
downstream of HLA–DRA. The top SNPs in 2 association
peaks in Asians (Figure 2A) were rs9277554 (P5 3 3
1027) near HLA–DPB1 and rs6903608 (P5 1 3 1026) in
HLA–DRB9 (betweenHLA–DRA andHLA–DRB1).
We also analyzed associations in imputed HLA
alleles in the European and Asian subsets (Supplementary
Table 3, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.40040/
abstract) and conducted a meta-analysis to assess hetero-
geneity. Of 41 alleles (of a total of 361) with significant
(P, 0.0001) associations in Europeans, Asians, or in the
meta-analysis, 17 had an I2 value of.80%, indicating high
heterogeneity, with an I2 value of 96.4 for HLA–
DQA1*0103 (OR in Europeans [OREuro] 0.45, and OR in
Asians [ORAsia] 1.56) and an I
2 value of 94.9 for HLA–
DQB1*0201 (OREuro 2.38 and ORAsia 1.03). In addition, 7
associations in Asians (all in HLA–DPA1/DPB1) could not
be analyzed in Europeans due to low frequency.
KLRG1 region. In order to determine whether
there might be associations in Europeans with untyped
SNPs in the KLRG1 region, we imputed up to the 1000
Genomes reference panel starting from the set of SNPs
common to both the Omni2.5M and Illumina 610K plat-
forms. Supplementary Figure 4 (available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40040/abstract) shows associations of geno-
typed and imputed SNPs in the KLRG1 region for Euro-
pean and Asian participants separately. These data
continued to show an Asian-only effect of multiple
KLRG1 SNPs on SS risk. Supplementary Table 4 (avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40040/abstract)
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shows the allele frequencies of the suggestive KLRG1
SNPs in various participant subgroups in our data set, indi-
cating that the external controls were similar to internal
controls, and that effect sizes were higher in the Chinese
cluster than in the Japanese cluster.
Representative SNPs and multivariate modeling.
We selected 24 representative SNPs in 20 regions with at
least 2 suggestive (P, 13 1025) or stronger associations in
any of our 3 GWAS (all subjects, Europeans, and Asians)
and from the top hits (or proxies) in published European
(6) and Asian (7) GWAS (see Patients and Methods). Sup-
plementary Table 2 (available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40040/abstract) contains details of the SNP/proxy selection,
and Supplementary Table 5 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40040/abstract) contains results from
the 3 GWAS. Although STAT4 and IRF5 SNPs did not
Figure 2. Major histocompatibility complex association plots. A, Asian subgroup. B, European subgroup. Inset. Relative positions of top single-
nucleotide polymorphisms and HLA genes from dbSNP. C, European subgroup (blue) with sample sizes (460 cases and 1,125 controls) equal to
those in the Asian subgroup (red).
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meet the criteria for suggestive associations in our Asian
GWAS, the ORs for these SNPs were similar across anal-
yses. TNFAIP3 also had similar ORs across analyses and
has been implicated previously in both European (23)
and Asian (7) studies. Interestingly, the results of this
analysis suggested that one of the GTF2I SNPs may be
associated in Europeans, although it previously was impli-
cated only in Asians (7). According to our data, BLK and
CXCR5 SNPs had a stronger effect in Asians, whereas the
effect of IL2A was much lower.
We also performed multivariate modeling of these
SNPs in the European and Asian subgroups separately,
adjusting for intra-European and intra-Asian PCs,
respectively (see Patients and Methods). We executed
logistic regression analysis with backward selection, with
thresholds of P, 0.01 for the European subset and
P, 0.05 for the Asian subset due to the smaller sample
size. The results of this analysis are shown in Supplemen-
tary Table 6, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40040/abstract. These data continue to support that
GTF2I is a risk variant in Europeans and also indicate
that the effect of the PRCC–SH2D2A region may be
more prominent in Asians or non-Europeans.
Investigation of sources of heterogeneity. As
shown in Supplementary Figure 5 (available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40040/abstract), we plotted the heterogeneity
P value from the Q statistic for the 24 representative SNPs
between the European and Asian analyses versus the differ-
ence in MAF between controls in the 2 population groups.
Although most of these SNPs had highly significant allele
frequency differences, there was also substantial heteroge-
neity of association; i.e., the frequency differences did not
fully explain these differences in association.
One potential source of genetic heterogeneity is
the heterogeneity of underlying subphenotypes in the
population groups. Table 3 shows the percentage of cases
positive for SSA/SSB autoantibodies, focus score criteria,
and OSS criteria. The percentage of cases positive for
these criteria was much higher in the Asian cluster com-
pared with the European cluster, which may be attribut-
able to ascertainment and/or associations between
ethnicity and subphenotypes (see below). Next, we studied
the degree to which global ancestry, represented by our
top 3 worldwide PCs, correlates with the subphenotypes
described above. As shown in Table 3, we observed
strongly significant correlations between PC1 (European/
Asian axis) and all 3 subphenotypes (for SSA/SSB,
r520.27 [P5 5 3 10247); for focus score, r520.18
[P5 23 10221]; for OSS, r520.12 [P5 23 10214]). We
also observed strongly significant correlations between
PC3 (American Indian/non–American Indian axis) and
the focus score and OSS, although the correlation coeffi-
cients were modest (absolute value,0.1).
Because it is possible that the relationship between
ancestry and subphenotype was confounded by the geo-
graphic recruitment site, we adjusted for site via meta-
analysis and provide site-specific statistics for PC1 (see
Supplementary Table 7, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40040/abstract). The mean value for PC1 was
higher or equal throughout in the subphenotype-negative
versus the subphenotype-positive cases, with the exception
that values were slightly lower for the India site (SSA/SSB)
or the Denmark and JHU sites (OSS). We observed a very
strong association between SSA/SSB status and PC1, both
adjusted for strata (meta-analysis P5 43 10215, heteroge-
neity Q5 0.38) and within the sites having the most vari-
ance in PC1 (i.e., higher power to detect associations): for
UCSF, P5 8 3 1027; for Argentina, P5 1 3 1025; for
UK, P5 0.00065; and for JHU, P5 0.0040. For the focus
score and OSS, the strata-adjusted P values were P5 4 3
1025 and P5 0.071, respectively, and the most strongly
Table 3. Subphenotype differences between the European and Asian clusters, and correlations with
the top 3 worldwide PCs, in SICCA participants*
SSA/SSB Focus score OSS
European cluster, no. meeting
criteria/total no. (%)
553/1,663 (33) 526/1,568 (34) 1,126/1,600 (70)
Asian cluster, no. meeting
criteria/total no. (%)
439/704 (62) 351/647 (54) 575/680 (85)
Top 3 worldwide PCs
PC1, r (P) 20.27 (5 3 10247) 20.18 (2 3 10221) 20.12 (2 3 10214)
PC2, r (P) 20.025 (0.16) 0.0053 (0.77) 20.013 (0.49)
PC3, r (P) 20.035 (0.055) 20.054 (0.0034) 20.050 (0.0059)
* PC15 principal components cluster 1; SICCA5 Sj€ogren’s International Collaborative Clinical Alli-
ance; OSS5 ocular staining score.
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associated strata is Argentina for both (P5 5 3 1026 and
P5 0.0061, respectively). We concluded that the degree of
European ancestry is likely to be protective for these
subphenotypes (see Discussion).
Finally, to understand whether this difference was
driving the apparent European and Asian heterogeneity,
we re-analyzed our data using only cases positive for all 3
subphenotypes. As shown in Figure 3, we plotted the 95%
CIs for associations in the European and Asian cases, for
all SS cases, and for only those meeting all 3 subphenotype
criteria. In most cases, the 95% CIs for associations in the
2 European groups and the 2 Asian groups were more sim-
ilar to each other than to the 95% CIs for associations in
the 2 groups meeting 3 criteria, indicating that sub-
phenotypes are not driving differences in association. A
notable exception was HLA–DPB1, for which the 95% CIs
in Europeans became more similar to those in Asians
when the analyses were restricted to cases positive for 3 cri-
teria; HLA–DPB1 was associated with positive SSA/SSB
and focus score status in both Europeans (for SSA/SSB,
OR 1.69 [P5 1.3 3 1028]; for focus score, OR 1.36
[P5 0.00071]) and Asians (for SSA/SSB, OR 1.64
[P5 0.00032]; for focus score, OR 1.47 [P5 0.0049]). It
was common in our study for effect sizes to become stron-
ger when the analyses were restricted to cases positive for
all 3 criteria; this was particularly true forHLA–DQB1 and
HLA–DQA1 in Europeans. HLA–DQA1 and HLA–DQB1
alleles were very strongly associated with SSA/SSB and
focus score status in the European participants (for SSA/
SSB, OR 4.42 [P5 1.2 3 10234] and OR 3.20 [P5 1.0 3
10232], respectively; for focus score, OR 2.98 [P5 1.6 3
10221] and OR 2.52 [P5 3.7 3 10224], respectively) but
not in the Asian participants.
DISCUSSION
The current study is the first international multi-
ethnic GWAS of SS and to our knowledge is the only inter-
national cohort with standardized deep phenotyping. Thus,
it is particularly well-suited to assess relationships between
ancestry and genetic etiology and how these may differ
depending on the clinical subtypes of SS, particularly for
the 2 largest ethnic groups, Europeans and Asians.
The results of our GWAS implicate several novel
suggestive regions of association (having at least 2 SNPs
with a P value of less than 1 3 1025). Two of these,
SH2D2A and KLRG1, have been associated with other
autoimmune diseases. It has been suggested (24) that a P
value more liberal than standard genome-wide significance
(P, 5 3 1028) is appropriate in this case, because genes
are often associated with multiple autoimmune diseases
and involve overlapping clinical subphenotypes. SH2D2A
has been associated with juvenile rheumatoid arthritis
(25), multiple sclerosis (26), and inflammatory neuropa-
thies (27,28). SH2D2A encodes a T cell–specific adapter
protein (TSAd) expressed in activated T cells, natural
Figure 3. Associations in Europeans versus associations in Asians. Cases designated 3-positive are positive for the SSA/SSB, focus score, and
ocular staining score criteria. The single-nucleotide polymorphisms are ordered according to decreasing heterogeneity (het) based on higher Q
values. 95% CI5 95% confidence interval.
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killer cells, and endothelial cells and is thought to function
in T cell signal transduction (29). We also found regulatory
evidence for this region: it has been shown to bind to
CEBPB, a regulator of immune and inflammatory
responses, and our top SNPs in this region are within
DNase I hypersensitivity peaks for numerous cell types.
KLRG1 has been shown to be associated with SLE in a
previous study (22) that examined both adult and
childhood-onset SLE in multiple ethnic groups. In that
study, significant haplotypes varied by ethnicity, with the
most significant haplotype being in Asian Americans, and
with European Americans having no significantly associ-
ated haplotype. This corroborates our finding of KLRG1
being associated with SS only in Asians.
The strongest novel region in our 3 GWAS was
observed in the European GWAS (OR 1.5, P5 63 1028)
in LOC105370283, a noncoding RNA on 13q31.1 that is
near pseudogene PTMAP5. This region was associated
(P5 5 3 1029) with C-reactive protein, a biomarker of
inflammation, in the Framingham cohort (30) and contains
a DNase I hypersensitivity site for human retinal epithelial
cells. Another interesting suggestive region was NFAT5;
members of the NF-AT family of proteins are transcription
factors involved in the immune response.
Striking differences between our European and
Asian GWAS pertain to the significance and locations of
MHC associations. The locations of MHC peaks in
Europeans are consistent with those observed in a previous
study (6), which also identified genes HLA–DQA1, HLA–
DQB1, and HLA–DRA as being most significant. The
peaks observed in the Asians in our study are similar to the
2 previously reported independent association signals (7);
both studies showed an association peak at HLA–DPB1.
Although the top peak reported in ref. 7 was between
HLA–DRB1 and HLA–DQA1, HLA–DRB9 is within the
same region of long-range linkage disequilibrium in MHC
class II. We observed high heterogeneity between Euro-
pean and Asian associations in our representative markers
for the peakMHC regions. Similarly, high MHC heteroge-
neity between European and Chinese participants has
recently been reported in SLE (31).
We have shown that the first worldwide ancestry
PC is significantly associated with subphenotypes, espe-
cially SSA/SSB autoantibody production, even within sites
and adjusting for site differences. Because this PC
distinguishes between European and Asian clusters, this
could be attributed to either the presence of Asian ances-
try or the absence of European ancestry. However, associa-
tion of PC1 with subphenotypes within Argentinians, and
a much weaker association with the American Indian axis
(PC3), leads us to believe that the degree of European
ancestry is primarily driving the PC1 association. Further
work is needed to confirm this finding, with more detailed
ancestry admixture data. If European ancestry is indeed
protective for all SS subphenotypes, this implies that Euro-
pean ancestry is protective for SS in general, as has been
seen in SLE. This is consistent with a study by Maldini
et al (12), which demonstrated a higher prevalence of SS
and SS autoantibodies in non-Europeans versus
Europeans in the greater Paris area. More population-
based studies of SS prevalence are needed to confirm this
hypothesis.
Finally, we demonstrate that the heterogeneity of
association seen in many of the top regions is not
explained, in most cases, by differing subphenotype dis-
tributions within different ethnic groups. Allele frequen-
cies in these SNPs differed significantly between the
European and Asian subgroups and likely reflect different
underlying haplotype structures, as has been shown for
KLRG1 in SLE (22). Because associated variants are likely
only tagging the actual causal variants, whether disease-
causing mutations are present in some populations but not
others or actually have different biologic effects in different
populations, will be the subject of future research.
A limitation of the current study is the paucity of
non-European control data sets. We included 2 European
control data sets derived from dbGaP (AREDS and
COGEND), which were genotyped on the same platform
and in the same laboratory concurrently. We identified
these in advance and thus were able to do duplicate
genotyping in a small subset of cases, for quality control. We
obtained a control data set for our Asian cluster,
IGANGWAS; however, it was genotyped on the Illumina
610 Quad platform, with only ;300,000 SNPs common to
both platforms. Thus, our Asian analysis was limited to this
smaller set, and comparisons between the ancestry groups
have this caveat. We performed an imputation of this data
set up to the 1.4 million post–quality control SNPs of the
Omni2.5M platform, and during the quality control process
compared the frequencies of the imputed external versus
internal controls (SICCA participants without SS) for each
SNP. The resulting Q–Q plot indicated systematic bias of
the imputed SNPs; therefore, we chose not to include these
data in the final analysis. Related to this, the 24 SNPs that
we used for heterogeneity comparisons and multivariate
modeling were drawn from the 300K overlap SNP set, which
sometimes resulted in weak proxies; this may have led to
overestimation or underestimation of the heterogeneity of
causal variants and their effects in multivariate models.
A related limitation of our study is that it may not
have had sufficient power to identify novel variants; recently
discovered variants in European (6) and Asian (7) cohorts
have identified risk alleles with ORs as low as 1.28 and 1.44,
respectively. Our all-subjects analysis had 80% power to
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detect ORs of 1.31–1.50 (for MAFs of 0.1–0.45), while our
European and Asian analyses had power to detect ORs of
1.49–1.75 and 1.65–2.01, respectively. We are very encour-
aged by the presence of suggestive genes already known to
influence autoimmunity, which we consider the most prom-
ising for future follow-up. These data are also available for
use in larger collaborations that may be more appropriately
suited to establishing novel associations.
Our SS case–control comparison used the ACR
2012 criteria for SS and included SS-negative subjects who
were positive for 1 criterion, with external Asian controls
added to increase power. Our results for the top SNPs were
very similar if the subjects positive for only 1 criterion are
omitted or if the newer 2016 ACR/European League
Against Rheumatism criteria (32) were used (see Supple-
mentary Table 8, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40040/abstract).
In summary, we have conducted the first multiethnic
GWAS in SS and analyses of European versus Asian associ-
ations. Several suggestive association peaks warrant further
follow-up in future studies, particularly in 2 regions previ-
ously implicated in autoimmune diseases. We observed
strong associations between SS subphenotypes and genetic
ancestry; however, this does not explain the heterogeneity of
the associations seen in the European versus Asian subpop-
ulations. Issues of genetic etiology, ancestry, and sub-
phenotype heterogeneity have been studied very little in SS
compared with autoimmune diseases such as SLE. Our
study gives new insights into these relationships and pro-
vides a basis for future work on the genetic etiology of SS.
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